OraSure Technologies will host an earnings conference call on February 25, 2026, discussing Q4 2025 results.
Quiver AI Summary
OraSure Technologies, Inc. will hold a conference call on February 25, 2026, at 5 p.m. ET to discuss its fourth quarter 2025 financial results and business updates. The call will be accessible via a webcast on the company's investor relations page, and interested participants are encouraged to register at least 10 minutes prior to the call. Details for accessing an archived version of the webcast will also be available shortly after the event. OraSure Technologies focuses on enhancing healthcare access and quality through innovative diagnostic testing solutions, serving various stakeholders in the healthcare sector globally. For more information, visit their website or contact their investor relations or media team.
Potential Positives
- OraSure Technologies has scheduled its earnings conference call, showcasing transparency and commitment to shareholder communication regarding financial results and business developments.
- The conference call will be accessible via a webcast, enhancing engagement with investors and stakeholders by providing a convenient platform for information dissemination.
- OraSure's focus on transforming health through innovative diagnostic solutions positions the company as a leader in a growing market, highlighting its potential for future growth and impact in healthcare.
Potential Negatives
- None
FAQ
When is OraSure's fourth quarter 2025 earnings call?
OraSure's earnings conference call will be held at 5 p.m. ET on February 25, 2026.
Where can I access the earnings call webcast?
The webcast can be accessed on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations.
How can I register for the earnings conference call?
You can register for the call by clicking the webcast link and completing the prompts at least 10 minutes prior to the call.
Will the earnings call be available after the live event?
Yes, the webcast will be archived on OraSure's website shortly after the call has concluded.
What does OraSure Technologies specialize in?
OraSure Technologies specializes in rapid diagnostic tests and sample collection solutions to improve healthcare access and quality.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OSUR Insider Trading Activity
$OSUR insiders have traded $OSUR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OSUR stock by insiders over the last 6 months:
- NANCY J GAGLIANO purchased 2,100 shares for an estimated $4,981
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OSUR Revenue
$OSUR had revenues of $27.1M in Q3 2025. This is a decrease of -32.14% from the same period in the prior year.
You can track OSUR financials on Quiver Quantitative's OSUR stock page.
$OSUR Hedge Fund Activity
We have seen 52 institutional investors add shares of $OSUR stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERICAN CENTURY COMPANIES INC removed 1,870,319 shares (-89.9%) from their portfolio in Q3 2025, for an estimated $6,003,723
- ALTAI CAPITAL MANAGEMENT, L.P. added 1,586,488 shares (+73.4%) to their portfolio in Q3 2025, for an estimated $5,092,626
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 1,227,997 shares (-68.6%) from their portfolio in Q3 2025, for an estimated $3,941,870
- MILLENNIUM MANAGEMENT LLC added 878,151 shares (+71.1%) to their portfolio in Q3 2025, for an estimated $2,818,864
- KENT LAKE PR LLC added 567,860 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,822,830
- GOLDMAN SACHS GROUP INC added 373,743 shares (+356.9%) to their portfolio in Q3 2025, for an estimated $1,199,715
- MORGAN STANLEY removed 348,498 shares (-51.8%) from their portfolio in Q3 2025, for an estimated $1,118,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit
www.orasure.com
|
Investor Contact:
Jason Plagman VP, Investor Relations [email protected] |
Media Contact:
Amy Koch Director, Corporate Communications [email protected] |
